breast cancer and semaglutide A new Penn Medicine study of more than 110,000 women found that those who took GLP-1 medications were about 30% less likely to develop than those who did not. Presented Unconventional Applications of Semaglutide and

This includes

Clinical Guideline CG189

This means less liquid under the skin, potentially less injection site discomfort, and faster absorption

Some studies have raised concerns that GLP-1 receptor agonists like Ozempic may increase the risk of pancreatic inflammation, which could contribute to the development of cancer

That's a description of fit, not a recommendation - whether GLP-1 medication of any kind is appropriate for a given person is a clinical determination made by a licensed provider reviewing that person's actual health history, not something this article or any marketing page can establish in advance